Nature Study 2022

Study published in Nature shows the Mirvie RNA platform can effectively identify 75% of pregnancies who later develop preeclampsia, months in advance.

Study analyzed RNA in 2,539 blood samples from 1,840 women in the United States, Europe and Africa.

Rasmussen, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022.

FINDINGS:

RNA messages change over time as pregnancy progresses, revealing the biology of fetal development and other dynamic processes.

RNA messages can be used to establish pregnancy dating, with an accuracy comparable to second-trimester ultrasound and superior to third-trimester ultrasound.

The Mirvie RNA Platform can provide a simple, objective, and actionable assessment of preeclampsia risk.

CLINICAL SIGNIFICANCE:

The Mirvie RNA Platform provides an objective assessment of risk independent of a woman’s demographics and clinical risk factors (e.g. race, age).

Superior to prediction based on clinical factors.¹

Clinical risk factors can be complex and subjective, difficult to apply consistently to guide care.^2,3

For every 100 patients who have at least 1 high risk factor for PE, 54 do not receive a recommendation to take aspirin. For those with 2 or more moderate risk factors, only 3.6-6.7% receive a recommendation to take aspirin.³

“Our approach opens new therapeutic windows to effectively decrease maternal and neonatal morbidity and mortality.” - Nature Study Authors: Rasmussen, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022.

1. Tan, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2018 2. USPSTF, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 3. Krishnamurti, et al. Use of a Smartphone App to Explore Potential Underuse of Prophylactic Aspirin for Preeclampsia. JAMA Netw Open. 2021